Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific share repurchase transaction executed on June 2, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,400,000 Ordinary shares of 25 pence each.
- Purchase Date: June 2, 2011.
- Price Range: Highest price paid was 1,303 pence per share; lowest price paid was 1,287 pence per share.
- Treasury Holdings (Settled): 498,074,284 shares (8.80% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,174,284 shares (9.68% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,158,861,816 shares.
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 1,400,000 repurchased shares. This transaction increased the proportion of shares held in Treasury to 9.68% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,158,861,816) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the impact of the 1,400,000 share cancellation on the total issued share capital.
- Monitor the settlement status of the 1,400,000 shares to confirm the final Treasury holding percentage.